Hepatitis B und C: von der molekularen Virologie zu neuen Perspektiven in der Therapie

Herrn Prof. Dr. Dr. h.c. mult. H. E. Blum zum 70. Geburtstag

Schlüsselwörter

Hepatitis B - Hepatitis C - molekulare Virologie - Pathologenese - antivirale Therapie

Keywords

hepatitis B - hepatitis C - molecular virology - pathogenesis - antiviral therapy

• Literatur

• 1 Assan R, Fredj G, Larger E et al. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete et Metabolisme 1994; 20: 49-52
• 2 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482-496
• 3 Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13: 48-64
• 4 Blum HE. Genetic variants of hepatitis B virus and their clinical significance. Schweiz Rundsch Med Prax 1992; 81: 974-977
• 5 Blum HE, Wieland S, von Weizsäcker F. Gene therapy: basic concepts and applications in gastrointestinal diseases. Digestion 1997; 58: 87-97
• 6 Charnay P, Pourcel C, Louise A et al. Cloning in Escherichia coli and physical structure of hepatitis B virion DNA. Proc Natl Acad Sci U S A 1979; 76: 2222-2226
• 7 Dallmeier K, Schultz U, Nassal M. Heterologous replacement of the supposed host determining region of avihepadnaviruses: high in vivo infectivity despite low infectivity for hepatocytes. PLoS Pathog 2008; 4: e1000230
• 8 Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1: 695-698
• 9 EASL. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420
• 10 Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J 2013; 10: 239
• 11 Gripon P, Diot C, Theze N et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988; 62: 4136-4143
• 12 Gripon P, Rumin S, Urban S et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99: 15655-15660
• 13 Kittner JM, Sprinzl MF, Grambihler A et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virology 2012; 54: 93-95
• 14 Köck J, Nassal M, MacNelly S et al. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001; 75: 5084-5089
• 15 Lanford RE, Chavez D, Brasky KM et al. Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A 1998; 95: 5757-5761
• 16 Lucifora J, Arzberger S, Durantel D et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011; 55: 996-1003
• 17 Marion MJ, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol 2010; 640: 261-272
• 18 Mason WS, Seal G, Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol 1980; 36: 829-836
• 19 Maynard JE, Berquist KR, Krushak DH et al. Experimental infection of chimpanzees with the virus of hepatitis B. Nature 1972; 237: 514-515
• 20 McClary H, Koch R, Chisari FV et al. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-2264
• 21 Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008; 134: 235-249
• 22 Nassal M. New insights into HBV replication: new opportunities for improved therapies. Future Virol 2009; 4: 55-70
• 23 Ni Y, Lempp FA, Mehrle S et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2013;
• 24 Offensperger WB, Offensperger S, Walter E et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993; 12: 1257-1262
• 25 Pasek M, Goto T, Gilbert W et al. Hepatitis B virus genes and their expression in E. coli. Nature 1979; 282: 575-579
• 26 Petersen J, Dandri M, Mier W et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341
• 27 Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010-1017
• 28 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849
• 29 Schmid B, Rösler C, Nassal M. A high level of mutation tolerance in the multifunctional sequence encoding the RNA encapsidation signal of an avian hepatitis B virus and slow evolution rate revealed by in vivo infection. J Virol 2011; 85: 9300-9313
• 30 Senior JR, London WT, Sutnick AI. The Australia antigen and role of the late Philadelphia General Hospital in reducing post-transfusion hepatitis and sequelae. Hepatology 2011; 54: 753-756
• 31 Serfaty PT, Bedossa P, Opolon P , The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832
• 32 Simmonds P, McOmish F, McCullough P et al. Contamination of immunoassay controls with hepatitis C virus (letter). Lancet 1992; 339: 1607
• 33 Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415
• 34 Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?. J Hepatol 2013; 58: 205-209
• 35 Thimme R, Spangenberg HC, Blum HE. Chronische Hepatitis B. Dtsch med Wochenschr 2008; 133: 135-138
• 36 Thimme R, Spangenberg HC, von Weizsäcker F et al. T-Zell-Antwort bei Hepatitis B und C: von der Viruselimination bis zum hepatozellulären Karzinom. Dtsch med Wochenschr 2002; 127: 2277-2279
• 37 Thimme R, Wieland S, Steiger C et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76
• 38 Valenzuela P, Gray P, Quiroga M et al. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 1979; 280: 815-819
• 39 Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
• 40 Walter E, Keist R, Niederoest B et al. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996; 24: 1-5
• 41 Wieland S, Thimme R, Purcell RH et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101: 6669-6674
• 42 Wieland SF, Eustaquio A, Whitten-Bauer C et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 2005; 102: 9913-9917
• 43 Wieland SF, Spangenberg HC, Thimme R et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004; 101: 2129-2134
• 44 Yan H, Peng B, He W et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013; 87: 7977-7991
• 45 Yan H, Zhong G, Xu G et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049
• 46 Yan RQ, Su JJ, Huang DR et al. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. J Cancer Res Clin Oncol 1996; 122: 289-295
• 47 Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994; 68: 2026-2030